Inovio Pharma (INO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.30 +8.33%
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.54 million versus the consensus estimate of $5.16 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Target raises full-year sales forecast amid ongoing turnaround drive
- Ocean Power Technologies revises fiscal 2026 results after audit
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
